In-vitro Evaluation of the Siddha Formulation Mahaveera Mezhugu (MVM) for Anti-Cancer Activity Against MCF-7 Human Breast Cancer Cells

Over one in ten new cases of cancer detected in women are related to breast cancer, making it the most common disease diagnosed in this demographic. It is the second leading cause of cancer-related deaths worldwide for women. The many cancer treatments and their potential adverse effects made people aware of the need to look for safe, affordable substitutes for cancer treatment. The Siddha system can offer a lot of formulations in the management of breast cancer. There are also many literary works that facilitate this. Efficacy of Mahaveera Mezhugu (MVM) is a Herbo-mineral siddha preparation it is indicated for Vatharogam, Megarogam. This MVM has been used for siddha clinically to treat breast cancer. but there is no scientific data to validate this medicine. Hence this study aims to evaluate the anticancer potential of Mahaveera Mezhugu through an in-vitro study in the MCF-7 Human Breast cell line, determined by dimethyl sulphoxide (DMSO, MTT and Annexin V- Fitc apoptosis by flow cytometry assay. LC50 concentration was found at 5.1879371 µg/mL. The Siddha system, which combines many well-researched drugs, has shown clinically significant improvements in the treatment of breast cancer. Further research and large randomized control trial are needed to determine the effects of the drug.